BCL2 and Miyoshi myopathy: Although there is still no evidence concerning a role of VEGF signaling in MM drug resistance, it confers chemoresistance in several types of solid and hematological tumors (Dias et al., 2002; Belcheva et al., 2004; Zhang et al., 2006; Hua et al., 2014; Nusrat et al., 2016; Bendardaf et al., 2017) and involves anti-apoptotic effectors that play a role also in MM-associated drug resistance such a as Bcl2 and survivin (Gerber et al., 1998; Tran et al., 2002).